-
公开(公告)号:US20150299224A1
公开(公告)日:2015-10-22
申请号:US14434344
申请日:2013-10-03
申请人: W. Michael SEGANISH , William T. MCELROY , Stephanie BRUMFIELD , Jason R. HERR , Larry YET , Jinhai YANG , James P. HARDING, III , Ginny Dai HO , Deen B. TULSHIAN , Wensheng YU , Michael K.C. WONG , Brian J. LAVEY , Joseph A. KOZLOWSKI , MERCK SHARP & DOHME CORP.
发明人: W. MICHAEL SEGANISH , WILLIAM T. MCELROY , STEPHANIE BRUMFIELD , JASON R. HERR , LARRY YET , JINHAI YANG , JAMES P. HARDING, III , GINNY DAI HO , DEEN TULSHIAN , WENSHENG YU , MICHAEL K.C. WONG , BRIAN LAVEY , JOSEPH A. KOZLOWSKI
IPC分类号: C07D513/04 , C07D417/04 , C07D417/14 , A61K45/06 , C07D405/14 , A61K31/4436 , A61K31/444 , A61K31/506 , C07D401/04
CPC分类号: C07D513/04 , A61K31/4436 , A61K31/444 , A61K31/506 , A61K45/06 , C07D401/04 , C07D401/14 , C07D403/04 , C07D405/14 , C07D413/04 , C07D417/04 , C07D417/14
摘要: The present invention relates to compounds which modulate interleukin-1 (IL-1) receptor-associated kinase 4 (IRAK4) and are useful in the prevention or treatment of inflammatory, cell proliferative and immune-related conditions and diseases. Specifically, provided herein are inhibitors of IRAK4 of Formula I and pharmaceutical compositions comprising such inhibitors, as well as methods therewith for treating IRAK4-mediated or -associated conditions or diseases.
摘要翻译: 本发明涉及调节白细胞介素-1(IL-1)受体相关激酶4(IRAK4)并可用于预防或治疗炎症,细胞增殖和免疫相关病症和疾病的化合物。 具体地,本文提供了式I的IRAK4和包含这些抑制剂的药物组合物的抑制剂,以及其用于治疗IRAK4介导的或相关的病症或疾病的方法。
-
公开(公告)号:US20180051027A1
公开(公告)日:2018-02-22
申请号:US15557195
申请日:2016-03-07
申请人: JONGWON LIM , MICHAEL D. ALTMAN , MATTHEW L. CHILDERS , CRAIG R. GIBEAU , GINNY DAI HO , HONCHUNG TSUI , MERCK SHARP & DOHME CORP.
发明人: JONGWON LIM , MICHAEL D. ALTMAN , MATTHEW L. CHILDERS , CRAIG R. GIBEAU , GINNY DAI HO , HONCHUNG TSUI
IPC分类号: C07D487/04 , A61K45/06 , A61K31/519 , A61K31/5377 , A61K31/635 , C07D495/04 , A61K31/4985 , A61K31/53
CPC分类号: C07D487/04 , A61K31/4985 , A61K31/519 , A61K31/53 , A61K31/5377 , A61K31/635 , A61K45/06 , C07D495/04
摘要: The present invention relates to carboxamide inhibitors of IRAK4 of formula (I) and provides compositions comprising such inhibitors, as well as methods therewith for treating IRAK4-mediated or -associated conditions or diseases.
-